← SynDRA
VERNAKALANT
SynDRA canonical compound SYN0033698 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | KCNA5 |
|---|
| Mechanism of action | Potassium channel blocker |
|---|
| Indication | atrial fibrillation (AF) |
|---|
| Disease area | cardiology |
|---|
All known targets
- KCNA5
- SCN5A
- KCNH2
- KCNJ3
- KCNJ5
- KCND3
- KCND2
Mechanisms of action (all sources)
- Potassium channel blocker
- KCNJ3 BLOCKER
- Kir3.1/Kir3.4 blocker
- KCNJ5 BLOCKER
- KCNA5 BLOCKER
- Voltage-gated potassium channel subunit Kv1.5 blocker
- KCNH2 BLOCKER
- KCND3 BLOCKER
- Voltage-gated potassium channel subunit Kv4.3 blocker
- SCN5A BLOCKER
- Sodium channel protein type V alpha subunit blocker
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLC6A4
- ACHE
- HTR1A
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- HTR2B
- HRH3
- ADORA1
- HDAC6
- F2
- ESR1
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
ATC classes
- C01B · ANTIARRHYTHMICS, CLASS I AND III
Cross-references
Synonyms
- RSD1235
- vernakalant hydrochloride
- brinavess
- vernakalant HCl
- UNII-9G468C8B13
- Vemakalant
- 9G468C8B13
- (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol
- 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-
- RSD-1235
- Vernakalant [INN:BAN]
- SCHEMBL410062
- CHEMBL2111112
- DTXSID60229659
- VBHQKCBVWWUUKN-KZNAEPCWSA-N
- CHEBI:135956
- EX-A2465
- ZINC22010910
- 4151AH
- AKOS027326205
- DB06217
- SB16873
- CS-0276
- API0014187
- RL05068
- 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
- vernakalantum
- RefChem:193993
- C01BG11
- DTXCID60152150
- Vernakalant [INN]
- MFCD16038313
- VERNAKALANT [MI]
- VERNAKALANT [WHO-DD]
- orb1678993
- GLXC-10779
- EBC-26687
- TQ0307
Look up VERNAKALANT in the interactive SynDRA portal →